Clinical Trials Directory

Trials / Unknown

UnknownNCT05710757

Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
University of Tennessee · Academic / Other
Sex
All
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess strength gains of proximal musculature in the nondominant upper extremity after implementing blood flow restriction (BFR) and myofascial release (MFR) with the supplementation of whey protein.

Detailed description

The purpose of this study is to assess strength gains of proximal musculature in the nondominant upper extremity after implementing blood flow restriction (BFR) and myofascial release (MFR) with the supplementation of whey protein. Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response. Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.

Conditions

Interventions

TypeNameDescription
OTHERmyofascial releaseMyofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
DEVICEblood flow restrictionBlood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
OTHERmyofascial releaseSham MFR.

Timeline

Start date
2023-10-16
Primary completion
2024-09-01
Completion
2024-09-01
First posted
2023-02-02
Last updated
2024-03-20

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05710757. Inclusion in this directory is not an endorsement.